Cryoport Inc. and Medipal Holdings Corporation have announced a multi-year strategic business alliance agreement to create an integrated regenerative medicine supply chain solution in Japan.   Cryoport and Medipal will partner to provide integrated, end-to-end distribution solutions for specialty cell and gene therapies that demand stringent temperature control, track and trace systems and global distribution. To meet demand from the increasing number of cell and gene therapies currently in deve...